RESIST-TB will host a webinar on 14 April 2022 on the latest results in the recent studies reporting on pretomanid-containing regimens, ZeNiX and TB-PRACTECAL, for the treatment of multidrug-resistant TB (MDR-TB).

12 April 2022 | Geneva:  The broth microdilution plate method represents a promising solution for comprehensive and quality-assured phenotypic drug susceptibility testing in tuberculosis (TB). Using this method up to 12 anti-TB agents can be tested simultaneously providing quantitative levels of resistance and aid individualized patient treatment decisions. The document provides an optimized plate design and standardized methodology to facilitate the improvement of the method for clinical use. The World Health Organization (WHO) calls on manufacturers to take forward this optimized method and make it available for programmatic use in resource-limited settings.

Researchers uncovered gaps in the care cascade for latent tuberculosis in the United States, including that less than half of people diagnosed with latent TB in 2016 and 2017 initiated treatment.

Lindsay McKenna, TB Project Co-Director at Treatment Action Group, gives an overview of the recent advances in the management of TB in children, and elaborates what needs to be done to meet the 2022 targets set in the 2018 UN High-Level Meeting political declaration to end TB suffering and deaths in children.

For people who contract tuberculosis (TB), the course of the disease can vary significantly. Most people do not become ill after infection with Mycobacterium tuberculosis, the bacterium that causes the disease. However, people can develop chronic pneumonia and some also have disease in the lymph nodes, bones or the central nervous system. Some TB patients have suppressed and exhausted immune responses, while others have an overacting response that makes the condition worse.

Bedaquiline-resistant tuberculosis is characterized in South Africa, where it has not been reserved as last resource for drug-resistant TB.

April 6, 2022: The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new grant awards to establish Tuberculosis Research Advancement Centers (TRACs). The centers will support the development of a next generation of tuberculosis (TB) researchers by providing focused mentoring and funding support for new investigators; opportunities for multidisciplinary and collaborative research; and training in laboratory and clinical settings. The total funding in the first year of these five-year grants is approximately $4.3 million.

A tool, developed by the Coalition of Women Living with HIV and AIDS in partnership with Treatment Action Group, designed to equip communities to use community-lead monitoring to better understand the TB screening and diagnostic services, and to translate findings into evidence-based advocacy.

7 Apr 2022: In the context of the mass influx of refugees from Ukraine into the European Union (EU), the European Economic Area (EEA) and other European countries, ECDC and the WHO Regional Office for Europe are releasing today an information note on testing for tuberculosis infection and screening for tuberculosis disease.

Tuberculosis is the second most common cause of death worldwide by an infectious pathogen; COVID-19 is the first. However, many aspects of TB's long history remain controversial.